Search
Searching with a thematic focus on HIV and AIDS, ARVs, HIV and AIDS treatment and care
Showing 141-150 of 162 results
Pages
- Document
TRIPS, drug patents and access to medicines: balancing incentives for R&D with public health concerns
Knowledge Economy Node, Development Gateway, 2003This interview with Professor Kieth Maskus looks into the impacts of the agreed deal on implementing the Doha declaration on TRIPs and public health.The questioning focuses on the likely impacts of the agreement on pharmaceutical companies, generic producers and developing countries but also looks into some of the likely interpretation of the wording of the agreement.Key points are:EDocumentUSAID report to Congress: care, treatment and support of persons living with AIDS
US Agency for International Development, 2002This paper states the areas of commitment, and reports on the work of USAID in treating and caring for patients with HIV/AIDS.The paper offers examples of USAID work in the following areas:antiretroviral therapyhome-based caretuberculosisopportunistic Infectionschildren affected by AIDSpsycho-social supportnutrition and food aidmicrofinanceIt also detDocumentPredicting the public health impact of antiretrovirals: preventing HIV in developing countries
AIDScience, 2003The authors discuss the potential public health impact of antiretroviral (ARV) drugs in developing countries. They use mathematical models to show that ARVs could prevent a substantial number of HIV infections, significantly reduce HIV prevalence, but would increase the transmission and prevalence of drug-resistant strains of HIV.DocumentIAEN Annual Conference 2003: "Current Issues in the Economics of HIV/AIDS"
International AIDS Economics Network, 2003This webpage presents draft versions of most of the papers that were presented at the IAEN Annual Conference 2003, along with many others whose authors wished that their papers be available on the Web site.Subject covered include: the financing of HIV/AIDS treatment; resource needs; drugs pricing; HIV/AIDS and intellectual property rights; HIV/AIDS and education.DocumentZimbabwe: antiretroviral therapy program: issues and opportunities for initiation and expansion
Development Experience Clearinghouse, USAID, 2003This report presents the findings of an assessment of the readiness and capacity of Zimbabwe’s health sector to deliver the range of services and manage the health commodities required for effective antiretroviral (ART) treatment.The paper finds that the country’s public and private sector health providers have a great depth of experience and the team identified the service delivery and logistiDocumentAntiretroviral treatment in developing countries: the peril of neglecting private providers
British Medical Journal, 2003New initiatives and global partnerships are trying to increase access to antiretroviral drugs. However, these initiatives largely ignore the fact that most poor people who suspect they have a sexually transmitted infection seek care in the private sector.DocumentAccess to antiretroviral drugs in Brazil
The Lancet, 2002Since 1996, the Brazilian Ministry of Health has guaranteed free and universal access to antiretroviral treatment for people living with HIV/AIDS. Implementation of this policy has had political, financial, and logistical challenges.DocumentGeneric competition, price and access to medicines: the case of antiretrovirals in Uganda
Oxfam, 2002This paper outlines the findings of Oxfam research into the accessibility of ARV therapy in Uganda since 2000. During that year two important events improved access to these medicines. First, five drug companies agreed to reduce the price of some ARVs under a UNAIDS scheme.DocumentAIDS, growth and distribution in South Africa
Centre for Social Science Research, University of Cape Town (UCT), South Africa, 2002How is the AIDS pandemic affecting growth and distribution in South Africa, and what are the economic impacts for workers likely to be?